Enzyme Replacement Therapy Market is Expanding Steadily
Future Market Insights recently published research findings that the global enzyme replacement therapy market is predicted to increase at 6.5% CAGR over the forecast period 2018–2028. It also finds the global market for enzyme replacement therapy is expected to exceed $ 13,776.2 million (US dollars) by the end of 2028, attesting the highest growth rate by Japan, which is expected to expand at 12.5% CAGR over 2018–2028. The developing healthcare infrastructure and awareness programs in regions of Asia Pacific and China is expected to play a part in revenue growth for the global enzyme replacement therapy market.
Some key research findings include:
- Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of $ 6,448.3 million (US dollars) between 2018 and 2028
- When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
